大B细胞淋巴瘤嵌合抗原受体T细胞（CAR-T）疗法的一大进步：了解耐药性的分子决定因素 - Suppr

Suppr

超能文献

A STEP ahead for CAR-T cell therapy of large B cell lymphoma: understanding the molecular determinants of resistance.

作者信息

Mouhssine Samir, Maher Nawar, Gaidano Gianluca

机构信息

Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.

Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.

出版信息

Transl Cancer Res. 2023 Nov 30;12(11):2970-2975. doi: 10.21037/tcr-23-1396. Epub 2023 Nov 17.

DOI:10.21037/tcr-23-1396

PMID:38130313

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10731332/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d31d/10731332/2e6bd45f28ab/tcr-12-11-2970-f1.jpg

相似文献

A STEP ahead for CAR-T cell therapy of large B cell lymphoma: understanding the molecular determinants of resistance.大B细胞淋巴瘤嵌合抗原受体T细胞（CAR-T）疗法的一大进步：了解耐药性的分子决定因素

Transl Cancer Res. 2023 Nov 30;12(11):2970-2975. doi: 10.21037/tcr-23-1396. Epub 2023 Nov 17.

Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.阿基仑赛注射液：嵌合抗原受体 T 细胞治疗复发/难治性大 B 细胞淋巴瘤的临床数据。

Ann Pharmacother. 2021 Mar;55(3):390-405. doi: 10.1177/1060028020944233. Epub 2020 Jul 22.

Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.在美国，对于经过二线或多线系统性治疗后复发或难治性大 B 细胞淋巴瘤的成年患者，与 lisocabtagene maraleucel 相比，axicabtagene ciloleucel 的成本效益。

J Med Econ. 2022 Jan-Dec;25(1):541-551. doi: 10.1080/13696998.2022.2065787.

Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.CD19 导向嵌合抗原受体 T 细胞疗法治疗转化型非滤泡性淋巴瘤的结果。

Transplant Cell Ther. 2023 Jun;29(6):349.e1-349.e8. doi: 10.1016/j.jtct.2023.02.021. Epub 2023 Mar 5.

The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.在美国，阿基仑赛二线治疗大 B 细胞淋巴瘤的成本效益：ZUMA-7 试验的经济学评价。

Transplant Cell Ther. 2022 Nov;28(11):750.e1-750.e6. doi: 10.1016/j.jtct.2022.08.010. Epub 2022 Aug 12.

Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.接受 axi-cel 治疗的复发或难治性大 B 细胞淋巴瘤患者的结局和影响因素：一项意向治疗分析结果。

Leuk Lymphoma. 2021 Jun;62(6):1344-1352. doi: 10.1080/10428194.2020.1864349. Epub 2020 Dec 29.

Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States.在中国和美国，阿基仑赛注射液作为弥漫性大B细胞淋巴瘤二线治疗的成本效益分析。

Ther Adv Hematol. 2023 May 23;14:20406207231168215. doi: 10.1177/20406207231168215. eCollection 2023.

Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.嵌合抗原受体 T 细胞疗法治疗胃肠道受累的大 B 细胞淋巴瘤患者的结果。

Transplant Cell Ther. 2021 Sep;27(9):768.e1-768.e6. doi: 10.1016/j.jtct.2021.05.018. Epub 2021 May 30.

A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.在日本进行的阿基仑赛治疗复发或难治性大B细胞淋巴瘤的2期研究：1年随访及生物标志物分析

Int J Hematol. 2023 Mar;117(3):409-420. doi: 10.1007/s12185-022-03494-7. Epub 2022 Nov 18.

Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.在美国，对于接受过两线或以上系统治疗后复发或难治性大 B 细胞淋巴瘤的成年患者，与 tisagenlecleucel 相比，axicabtagene ciloleucel 的成本效益。

J Med Econ. 2021 Jan-Dec;24(1):458-468. doi: 10.1080/13696998.2021.1901721.

引用本文的文献

Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.B细胞和T细胞淋巴瘤的液体活检：从实验台到病床旁

Int J Mol Sci. 2025 May 19;26(10):4869. doi: 10.3390/ijms26104869.

Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.惰性B细胞恶性肿瘤向侵袭性B细胞恶性肿瘤转变的分子机制

Cancers (Basel). 2025 Mar 6;17(5):907. doi: 10.3390/cancers17050907.

本文引用的文献

Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Concepts.《世界卫生组织血液淋巴系统肿瘤分类第5版——更新后的分类与新概念》中的大B细胞淋巴瘤

Cancers (Basel). 2023 Apr 13;15(8):2285. doi: 10.3390/cancers15082285.

Liquid biopsy in hematological malignancies: current and future applications.血液系统恶性肿瘤中的液体活检：当前及未来应用

Front Oncol. 2023 Apr 20;13:1164517. doi: 10.3389/fonc.2023.1164517. eCollection 2023.

CAR T Cell Therapy: A Versatile Living Drug.嵌合抗原受体 T 细胞疗法：一种多功能活体药物。

Int J Mol Sci. 2023 Mar 27;24(7):6300. doi: 10.3390/ijms24076300.

A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms.这项研究成果深入探讨了 CD19-CAR T 细胞耐药的机制，让人眼前一亮。

Cell Rep Med. 2023 Feb 21;4(2):100949. doi: 10.1016/j.xcrm.2023.100949.

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.针对大 B 细胞淋巴瘤中 CD19 的工程 T 细胞疗法的耐药性决定因素。

Cancer Cell. 2023 Jan 9;41(1):210-225.e5. doi: 10.1016/j.ccell.2022.12.005. Epub 2022 Dec 29.

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.嵌合抗原受体 T 细胞 CD19 在二线大 B 细胞淋巴瘤中的作用：来自 3 期临床试验的经验教训。美国移植和细胞治疗学会专家小组意见。

Transplant Cell Ther. 2022 Sep;28(9):546-559. doi: 10.1016/j.jtct.2022.06.019. Epub 2022 Jun 26.

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.循环肿瘤DNA监测可改善大B细胞淋巴瘤患者接受阿基仑赛注射液输注后的早期复发检测：一项前瞻性多机构试验的结果

J Clin Oncol. 2021 Sep 20;39(27):3034-3043. doi: 10.1200/JCO.21.00377. Epub 2021 Jun 16.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。

Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.使用肿瘤标志物连续动态分析进行个体化预后预测。

Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.

CAR T-cell therapy: Full speed ahead.嵌合抗原受体 T 细胞疗法：全速前进。

Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. doi: 10.1002/hon.2591.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验